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Introduction: Paroxysmal atrial fibrillation (PAF) is perhaps the most underdiagnosed 
mechanism of apparent cryptogenic stroke (CS). Various studies have shown that increasing 
the duration of monitoring can increase the diagnosis of PAF in CS.
Methods: We compared demographic and risk factors for ischemic stroke across different 
TOAST (Trial of ORG 10172 in Acute Stroke Treatment) stroke subtypes to look for   clinical 
differences between other subtypes and CS and subsequently performed periodic Holter 
  monitoring and imaging studies in apparent CS patients.
Results: Of the 298 patients with ischemic stroke, 17% had CS. Periodic holter monitoring 
enabled diagnosis of PAF in 29% of patients. Five of 51 patients with CS had recurrent ischemic 
stroke and all 5 were demonstrated as PAF on repeated Holter monitoring.
Conclusions: Long-term periodic rhythm monitoring in patients with apparent CS showed 
PAF in a significant percentage of CS patients, which altered subsequent treatment.
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Introduction
Understanding the etiological basis of acute ischemic stroke is important in optimizing 
treatment to reduce the chances of recurrent ischemic stroke (RIS).1 Warfarin is the 
accepted treatment for cardioembolic stroke,2 while antiplatelet drugs with or without 
carotid endartectomy or carotid artery stenting are the appropriate treatment for large 
artery atherosclerosis (LAA).3
Even with the most comprehensive in-patient evaluation, 20% to 30% of   ischemic stroke 
has undefined etiologies: cryptogenic stroke (CS).4–8 These patients are often   randomly 
assigned to treatment options depending upon the perceived etiology of the stroke by their 
physician. The American Heart Association/American Stroke   Association (AHA/ASA) 
guidelines9 help in identifying structural causes for stroke such as atherothrombosis or 
known cardiac causes (eg, known atrial fibrillation, low ejection fraction).
However, one of the most neglected aspects of stroke evaluation is intermittent 
rhythm disorders such as paroxysmal atrial fibrillation (PAF), which may not be evident 
within the suggested 24-hour telemetry period and is as important as chronic atrial 
fibrillation (CAF) as a risk factor for stroke. Therefore, we prospectively investigated 
the prevalence of PAF in apparent CS.
Methods
Patients with a first-ever ischemic stroke admitted to the University of Massachusetts 
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guidelines9 for a period of 7 years from 2002 to 2009 and were 
classified into subtypes according to TOAST (Trial of ORG 
10172 in Acute Stroke Treatment) criteria and   definitions.1 
Transient ischemic attacks (TIA), while not a part of the 
TOAST classification, were nevertheless included since they 
constitute a high risk group for subsequent stroke and may 
have PAF or CAF as an underlying mechanism. The study 
remains an ongoing project and data collected between 
2002 and 2009 were analyzed. Patients seen in the stroke 
  prevention clinic with a diagnosis of CS were included in 
the study for periodic follow-ups. Patients with   hemorrhagic 
stroke were excluded. The entire cohort of patients was 
transitioned from the inpatient service to follow-up in the 
stroke prevention clinic. All patients had a transthorasic 
echocardiogram (TTE) and those with normal TTE and no 
other obvious risk factors underwent a TEE to assess for left 
atrium, auricle, and aortic arch disease. Patients were clas-
sified as CS only after a full extensive work-up including 
cardiac studies, hypercoagulable studies, continued inpatient 
telemetry where indicated and computed tomography (CT) 
and CT angiogram followed by magnetic resonance imaging 
(MRI) of the brain where noncontrast CT was normal.
Protocol
At each 6-monthly visit, a comprehensive evaluation and med-
ical reconciliation were performed. The evaluation consisted 
of fasting lipid panel, glucose, C-reactive protein, Doppler 
studies of the neck, and 48-hour Holter monitoring.
PAF was defined as episodes of AF that lasted for less 
than 1 week and resolved spontaneously.10 To detect PAF, 
patients underwent periodic 48-hour Holter monitoring every 
6 months. Stroke-related risk factors (hypertension, diabetes 
mellitus, hyperlipidemia, past history of   myocardial   infarction 
[MI], coronary artery disease [CAD]),   demographics, and 
medication use were compared across different subtypes to 
assess for possible clinical differences between patients with 
CS and other stroke subtypes.
A subgroup analysis of all patients determined to have 
cardioembolic stroke (including newly diagnosed PAF and 
CAF) was performed to look for possible clinical similarities 
and differences between patients with CS with later defined 
PAF and those presenting as obvious cardioembolic stroke 
at onset. We also compared the subgroup of patients with 
CS and PAF and the subgroup of patients with CS without 
PAF to identify any differences that might again help to 
predict which patients with CS have an underlying cardiac 
arrhythmia, namely PAF.
statistical methods
One way analysis of variance (age) and Chi-square tests 
(risk factors, medications, gender) were used to compare the 
variables in the different groups, and a P-value , 0.05 was 
regarded as significant.
Results
Two hundred ninety-eight patients with ischemic stroke were 
evaluated. The mean age of the subjects was 63.16 ± 15.85 
years, and 56.7% of the patients with ischemic stroke were 
males. Subtype classification showed 54 (17%) cardioem-
bolic stroke, 74 (25%) LAA, 87 (29%) small artery disease, 
51 (17%) CS, and 32 (11%) TIA. A comparative analysis 
of demographics and risk factors including hypertension, 
hyperlipidemia, CAD, diabetes mellitus, past history of 
MI, and past history of TIA, yielded significant differ-
ence in age between the 5 groups (P = 0.043) (Table 1). 
A post-hoc Tukey test showed that patients with SAD were 
older than patients with CS (P = 0.076), but this difference 
did not reach   significance. There were no other significant 
d  ifferences between the groups. Two patients with initial 
CS developed early   subsequent PAF and therefore for 
Table 1 Demographic and risk factors compared across the 5 subgroups of ischemic stroke and transient ischemic attack
LAA CE SAD TIA CS P-value
Age 60.59 ± 14.94 65.66 ± 17.33 66.03 ± 14.73 64.89 ± 16.46 58.22 ± 15.94 0.043
gender 29 (39.2%) 
Female
22 (40.7%) 
Female
40 (46.0%) 
Female
9 (28.1%) 
Female
29 (56.9%) 
Female
0.102
45 (60.8%) 
Male
32 (59.3%) 
Male
47 (54.0%) 
Male
23 (71.9%) 
Male
22 (43.1%) 
Male
hTn 40 (54.1%) 29 (53.7%) 49 (56.3%) 18 (56.3%) 18 (35.3%) 0.149
hyper-lipidemia 42 (56.8%) 27 (50.0%) 42 (48.3%) 16 (50.0%) 24 (47.1%) 0.813
Previous Mi 7 (9.5%) 4 (7.4%) 4 (4.6%) 2 (6.3%) 3 (6.0%) 0.805
A-Fib 2 (3.8%) 14 (35.0%) 5 (8.6%) 4 (14.8%) 2 (7.4%) ,0.001
Diabetes 14 (18.9%) 11 (20.4%) 15 (17.2%) 5 (15.6%) 8 (16.0%) 0.965
CAD 9 (12.2%) 10 (18.5%) 9 (10.3%) 7 (21.9%) 7 (15.7%) 0.446
Abbreviations: AF, atrial fibrillation; CAD, coronary artery disease; CE, cardioembolic stroke; CS, cryptogenic stroke; HTN, hypertension; LAA, large artery atherosclerotic 
stroke; MI, myocardial infarction; SAD, small artery disease; TIA, transient ischemic attack.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
35
Atrial fibrillation in cryptogenic stroke
demographic purposes were kept in the CS category because 
at the time of stroke they did not have AF. Comparison 
between known cardioembolic stroke and CS did not yield 
any features that could predict or distinguish between the 
2 groups (Table 3).
The mean age of patients with CS in our study was 
58.22 ± 15.94 years and was not significantly lower than that 
for other stroke subtypes including CE strokes. We compared 
the medications that the patients were on at the time of their 
initial visit to the clinic. As was expected, the use of medica-
tions differed among patients (Table 2).
During the follow-up of patients with CS, based on 
48-hour Holter monitoring, 29% patients were diagnosed 
with PAF within a period of 1 year from initial evaluation. 
Patients with brief ,30-second nonrecurring PAF were 
not included in the analysis. There were no significant 
  demographic differences among groups.
RIS was seen in 5 patients (10% of all CS patients). All 
were associated with newly diagnosed PAF. No patient with 
RIS was on warfarin. MRI in 4 of these patients also showed 
bihemispheric subcortical infarcts vessel consistent with an 
embolic etiology for stroke.
Discussion
AF and atrial flutter account for about 10% of all strokes and 
50% of cardioembolic strokes.11,12 Patients with PAF have 
many episodes of asymptomatic AF.13,14 Both CAF and PAF 
are comparable for their risk of stroke.14,15 In patients with 
CS periodic rhythm monitoring may identify new PAF in 
approximately 1 in 20 patients.16
The incidence of CS in our study was 17%. Other 
population-based studies have shown the incidence of CS 
to be 30% to 40%5–8,17 which may be attributed to different 
sampling methods.
Based on the treating physician’s perception of the stroke 
subtype, patients with CS are often arbitrarily treated with 
warfarin or antiplatelet agents, as in our study (warfarin 14% 
and antiplatelet agents 53%).
We did not find any demographic differences between 
different ischemic stroke subtypes in spite of some studies 
suggesting that demographic data and risk factors may be 
significantly different across subtypes.17,18 Patients who had 
CS and were diagnosed with PAF had a higher incidence 
of diabetes, CAD, and past history of MI than CS patients 
without a diagnosis of PAF. Tayal et al also found that the 
incidence of diabetes was higher in patients of CS/TIA 
diagnosed with AF on mobile cardiac outpatient telemetry 
(MCOT).19 However these differences, while important, 
are not predictive of stroke subtype and are not helpful in 
individual treatment decisions.
AF/atrial flutter is a strong risk factor for stroke and is 
arguably the most important finding on cardiac work-up in 
patients with stroke. Treatment with warfarin and other oral 
anticoagulants provides a 44% greater relative risk r  eduction 
in recurrent stroke compared with antiplatelet therapy.16 
In spite of the importance of diagnosing PAF they are per-
haps the most under-studied mechanisms causing CS and no 
definitive guidelines are yet available for the follow-up and 
diagnoses of these disorders in patients with apparent CS. 
With periodic 6-monthly Holter monitoring, we found PAF 
Table 2 Medication use compared across the 5 subgroups of ischemic stroke and transient ischemic attack
LAA CE SAD TIA CS P-value
Antiplatelets 49 (66.2%) 22 (40.7%) 61 (70.1%) 23 (71.9%) 27 (52.9%) 0.003
AsA 25 (33.8%) 19 (35.2%) 26 (29.9%) 13 (40.6%) 17 (33.3%) 0.860
AsA/extended-release 
dipyridamole
21 (28.4%) 3 (5.6%) 26 (29.9%) 8 (25.0%) 9 (17.6%) 0.008
Clopidogrel 12 (16.2%) 4 (7.4%) 9 (10.3%) 5 (15.6%) 7 (13.7%) 0.565
Warfarin 10 (13.5%) 24 (44.4%) 4 (4.6%) 7 (21.9%) 7 (13.7%) ,0.001
statins 43 (58.1%) 31 (57.4%) 51 (58.6%) 14 (43.8%) 21 (41.2%) 0.184
ACe-inhibitors 24 (32.4%) 21 (38.9%) 31 (35.6%) 9 (28.1%) 13 (25.5%) 0.596
Other Anti-hTn 21 (28.4%) 27 (50.0%) 32 (36.8%) 12 (37.5%) 16 (31.4%) 0.138
Abbreviations: ACE, angiotensin-converting enzyme; ASA, aspirin; CE, cardioembolic stroke; CS, cryptogenic stroke; HTN, hypertensives; LAA, large artery atherosclerotic 
stroke; SAD, small artery disease; TIA, transient ischemic attack.
Table 3 Comparison of demographics, risk factors, and stroke 
recurrence in patients with cryptogenic stroke with and without 
paroxysmal atrial fibrillation
PAF present PAF absent P-value
n 15 (29.4%) 36 (70.6%)
Age 61.53 ± 16.28 56.74 ± 15.85 0.375
gender 8 (53.3%) Male 14 (38.9%) Male 0.371
7 (46.7%) Female 22 (61.1%) Female
hTn 6 (40.0%) 12 (33.3%) 0.751
hyperlipidemia 8 (53.3%) 16 (44.4%) 0.759
Previous Mi 1 (6.7%) 2 (5.6%) 1.000
Diabetes 4 (26.7%) 4 (11.1%) 0.213
Ris 5 (33.3%) 0 0.001
CAD 4 (26.7%) 4 (11.1%) 0.213
Note: *no comparison was made for the number.
Abbreviations: CAD, coronary artery disease; HTN, hypertension; MI, myocardial 
infarction; PAF, paroxysmal atrial fibrillation, RIS, recurrent ischemic stroke. Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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in 29% of our CS cases within a year, which changed the 
treatment in these patients from antiplatelet drugs to warfarin. 
Interestingly, all 5 RIS that occurred during the follow-up 
period were all in patients with CS, and delayed detection 
of PAF.
Different short-term follow-up strategies for diagnosing 
underlying PAF, such as automatic cardiac event recorders,20 
7-day external loop recorders,21 and 21-day MCOT,19 have 
been studied. Barthelemy et al monitored CS and TIA patients 
continuously using automatic cardiac event recorders for a 
mean period of 70.1 ± 30.9 hours and found PAF in 4 out 
of 28 (14.3%) patients with CS. Approximately 33% of AF 
episodes were missed in spite of the currently recommended 
thorough ECG and Holter monitoring.20 Jabaudon et al also 
found that external loop recorders for 7 days after acute stroke 
or TIA increased the detection of PAF and CAF by 5.7% 
(5/88) patients.21 Tayal et al found that 21-day MCOT enabled 
the diagnosis of 23% patients of CS/TIA with asymptomatic 
AF.19 However, unlike our study, they did not follow patients 
for a prolonged period after the acute ischemic stroke/TIA 
and may have missed some patient with potential cardioem-
bolic stroke. Because the natural history of PAF is unknown, 
it is difficult to state what the optimal duration of monitoring 
should be in patients with CS/TIA to diagnose PAF.22
In our study, RIS was seen exclusively in the CS with 
subsequent PAF. This underscores the importance of proper 
identification of stroke subtypes for initiating appropriate 
strategies for secondary prevention such oral anticoagulants 
in ischemic stroke patients with PAF.
While there may be no differentiating clinical features to 
distinguish CS patients who have PAF, some ECG fi  ndings 
seem to be more informative. Kolb et al, in a small study of 
33 patients where 297 episodes of PAF were detected using 
12-lead Holter monitoring, found that most of these epi-
sodes were triggered by monomorphic left atrial p  remature 
complexes.23,24,25 Similarly in some studies, patients with left 
atrial enlargement, spontaneous echo contrast were found to 
have a higher likelihood of PAF and c  ardioembolic events.26,27 
Some studies have identified patients with PAF poststroke 
that was short lived and associated with an i  ntracerebral 
hematoma. The authors argue that these short-lived episodes 
of AF may be triggered by the stroke itself. However if there 
is no other explanation for the etiology of stroke and it hap-
pens to be ischemic,28 PAF would still rank highly on the list 
as the underlying cause.
In conclusion, it seems that the present guidelines for 
rhythm monitoring for ischemic stroke are insufficient 
for detecting PAF, as shown by several studies as well as 
our own study. Increasing the duration of initial rhythm 
  monitoring along with periodic rhythm monitoring (either 
with Holter or poststroke 30-day event monitoring) may 
increase the yield of PAF in CS. Based on our and other 
studies, to optimize detection of PAF, periodic 3- to 6-month 
monitoring seems reasonable, especially if there is history of 
intermittent palpitations, radiological evidence of bilateral 
infarcts, or ECG evidence of monomorphic premature atrial 
contractions without significant cardiac or atherosclerotic 
disease. A recent ongoing randomized prospective trial using 
s  tandard arrhythmia monitoring versus an implantable device 
with a follow-up of 6 to 12 months may further enhance our 
  knowledge of the prevalence of PAF in CS.29
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